Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:CSBR

Champions Oncology (CSBR) Stock Price, News & Analysis

Champions Oncology logo

About Champions Oncology Stock (NASDAQ:CSBR)

Advanced Chart

Key Stats

Today's Range
$9.00
$9.72
50-Day Range
$9.11
$10.96
52-Week Range
$3.60
$11.99
Volume
32,633 shs
Average Volume
42,642 shs
Market Capitalization
$101.79 million
P/E Ratio
16.73
Dividend Yield
N/A
Price Target
$12.00
Consensus Rating
Buy

Company Overview

Champions Oncology, Inc. engages in the development and sale of technology solutions and products to personalize the development and use of oncology drugs. Its technology platform, TumorGraft, is a novel approach to personalizing cancer care based upon the implantation of human tumors in immune-deficient mice. It uses its technology to offer solutions to Translational Oncology Solutions, which includes pharmaceutical and biotechnology companies; and Personalized Oncology, which assists physicians in developing personalized treatment options for their cancer patients. The company was founded by James M. Martell and David Sidransky on June 4, 1985 and is headquartered in Hackensack, NJ.

Champions Oncology Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
86th Percentile Overall Score

CSBR MarketRank™: 

Champions Oncology scored higher than 86% of companies evaluated by MarketBeat, and ranked 148th out of 943 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Champions Oncology has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Champions Oncology has received no research coverage in the past 90 days.

  • Read more about Champions Oncology's stock forecast and price target.
  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Champions Oncology is 16.73, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 24.77.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Champions Oncology is 16.73, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 26.44.

  • Percentage of Shares Shorted

    1.57% of the float of Champions Oncology has been sold short.
  • Short Interest Ratio / Days to Cover

    Champions Oncology has a short interest ratio ("days to cover") of 2.6, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Champions Oncology has recently increased by 0.63%, indicating that investor sentiment is decreasing.
  • Dividend Yield

    Champions Oncology does not currently pay a dividend.

  • Dividend Growth

    Champions Oncology does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    1.57% of the float of Champions Oncology has been sold short.
  • Short Interest Ratio / Days to Cover

    Champions Oncology has a short interest ratio ("days to cover") of 2.6, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Champions Oncology has recently increased by 0.63%, indicating that investor sentiment is decreasing.
  • News Coverage This Week

    MarketBeat has tracked 16 news articles for Champions Oncology this week, compared to 4 articles on an average week.
  • Search Interest

    Only 2 people have searched for CSBR on MarketBeat in the last 30 days. This is a decrease of -33% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Champions Oncology insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    46.98% of the stock of Champions Oncology is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    41.30% of the stock of Champions Oncology is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Champions Oncology's insider trading history.
Receive CSBR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Champions Oncology and its competitors with MarketBeat's FREE daily newsletter.

CSBR Stock News Headlines

The #1 AI Energy Stock
Nearly $600 billion is projected to be spent on AI data centers this year. That's because the ones being built now will dwarf everything that came before them. Thanks to AI's ravenous hunger for power … They are beginning to morph into sprawling behemoths.
WWE Night Of Champions 2025 Full & Final Card
See More Headlines

CSBR Stock Analysis - Frequently Asked Questions

Champions Oncology, Inc. (NASDAQ:CSBR) posted its quarterly earnings data on Tuesday, March, 11th. The biotechnology company reported $0.31 EPS for the quarter. The biotechnology company earned $17.04 million during the quarter. Champions Oncology had a net margin of 10.97% and a trailing twelve-month return on equity of 656.65%.
Read the conference call transcript
.

Based on aggregate information from My MarketBeat watchlists, some other companies that Champions Oncology investors own include Intel (INTC), Gilead Sciences (GILD), Micron Technology (MU), NVIDIA (NVDA), AT&T (T), Advanced Micro Devices (AMD) and Bristol Myers Squibb (BMY).

Company Calendar

Last Earnings
3/11/2025
Today
6/30/2025
Fiscal Year End
4/30/2026

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - DRUGS
Sub-Industry
N/A
Current Symbol
NASDAQ:CSBR
Employees
143
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$12.00
High Stock Price Target
$12.00
Low Stock Price Target
$12.00
Potential Upside/Downside
+63.0%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Trailing P/E Ratio
17.64
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$7.28 million
Pretax Margin
10.92%

Debt

Sales & Book Value

Annual Sales
$50.15 million
Price / Cash Flow
N/A
Book Value
($0.14) per share
Price / Book
-52.57

Miscellaneous

Free Float
7,331,000
Market Cap
$101.79 million
Optionable
Optionable
Beta
0.37

Social Links

10 Stocks Set to Soar in Summer 2025 Cover

Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

This page (NASDAQ:CSBR) was last updated on 7/1/2025 by MarketBeat.com Staff
From Our Partners